Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

So, this is the news we were expecting. Main ta

Message Board Public Reply | Private Reply | Keep | Replies (3)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155057
(Total Views: 952)
Posted On: 10/20/2020 8:37:04 AM
Avatar
Posted By: TechGuru
So, this is the news we were expecting.

Main takeaway: the DSCM has found out that Leronlimab works. Why ?? trial continues and if we did not have any hope of meeting statistical significance they would not had recommended to continue the trial.

So this is the second time Leronlimab performs (first one being HIV), but more importantly now: IT WORKS FOR COVID-19.

This is extremely important.

As for the modifications to the trial:

We must have a very good p-value as the DSCM recons significance can be met @ 295 patients. Something important that has not been discussed here is that of the power of the trial. One can have a superb p-value, say 0.005 and still have a power of, say, 75%. The power of the trial depends on the number of patients and guarantees that there is no Type II error (so called false-negative error). The DSCM obviously accounts for this and that is why the interim values are way more stringent. The scheduling of another interim says that they forecast probable significance even with the lower levels of enrollment at that time.

The 42 days follow up is also positive. IF LL is showing benefit at 28 days, mostly with Critical, the statistics (SOC vs LL) will diverge as time goes by. So, this is an indirect differentiation of Critical patients and the DSCM has seen that monitoring patients will be beneficial (meaning it was beneficial to start with).

All together excellent news for us investors (long term). Leronlimab works in the COVID-19 world!!!!


(24)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us